Whole-body PET scans to study multiple sclerosis
Tests a full-body PET scanner to better assess nerve damage in multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Entire-body PET Scans for Multiple Sclerosis
Key facts
- Where
- Ladera Ranch, United StatesSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 55 years old?
Source: NCT04390009, who can take part
Where in United States
- Brain Health AllianceLadera Ranch, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Brain Health Alliance
- Trial code
- NCT04390009
- Record updated
- 6 October 2026
- Original description
To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.Read full original descriptionShow less
Exploratory Study of Entire-body PET Scans for Multiple Sclerosis
To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.
Inclusion: Multiple sclerosis (MS) patients diagnosed by a credentialed neurologist experienced with care of multiple sclerosis patients; Normal healthy subjects; Willing and able to lie motionless on the PET-CT scanner bed for at least 10 minutes and up to 20 minutes for the duration of the PET-CT medical imaging scan.
Exclusion: Any additional complicating medical illness other than MS including any other neuropsychiatric illness unrelated to MS diagnosed prior to the onset of initial symptoms of MS; Any known concomitant acute infection; Recent surgery, chemotherapy or radiation therapy; Diabetes or other metabolic-endocrine disorders; History of metastatic or locally invasive cancer; Pregnancy or breast feeding.